Impact of American Academy of Pediatrics Palivizumab Guidance for Children ≥29 and <35 Weeks of Gestational Age
| Autor: | Glenn Bushee, Tracy N. Zembles, Rodney E. Willoughby |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Palivizumab
Pediatrics medicine.medical_specialty business.industry viruses Gestational age Guideline 03 medical and health sciences 0302 clinical medicine Disease severity 030225 pediatrics Pediatrics Perinatology and Child Health Severity of illness medicine 030212 general & internal medicine business medicine.drug |
| Zdroj: | The Journal of Pediatrics. 209:125-129 |
| ISSN: | 0022-3476 |
| Popis: | Objectives To evaluate the impact of the American Academy of Pediatrics revised recommendations (2014) for palivizumab prophylaxis on respiratory syncytial virus (RSV) admissions and severity of illness among children ≥29 weeks and Study design We evaluated patients hospitalized with RSV infection from October 1, 2012, through April 30, 2017. RSV hospitalizations, community RSV activity, duration of hospitalization, disease severity, and mortality were reviewed. Data were compared before and after implementation of the guideline changes. Results A total of 91 patients were born at ≥29 weeks and Conclusions Implementation of the 2014 American Academy of Pediatrics guidelines regarding eligibility for palivizumab prophylaxis in older infants born preterm did not increase RSV hospitalizations or disease severity among children hospitalized for RSV at our hospital. Our data support continued adherence to the guidelines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect